Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
ROTTERDAM, the Netherlands, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a biotech company pioneering next-generation T cell therapies for solid tumours, today announced a EUR 10 million ...
Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to ...
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ...
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR) ...
Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the ...
EpimAb_Logo Planegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered ...
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback